HMG (Human Menopausal Gonadotropin)

HMG is a purified gonadotropin preparation extracted from the urine of postmenopausal women, delivering roughly 1:1 FSH and LH bioactivity per vial (standard 75 IU + 75 IU). Its mechanism is straightforward in concept but uniquely useful in practice: it bypasses the pituitary entirely and delivers both testicular signals directly, covering the one thing hCG monotherapy can't — FSH.

Dual Receptor Targeting: LH + FSH#

HMG's defining feature is that it hits both testicular receptor populations simultaneously. hCG only mimics LH. Recombinant FSH only provides FSH. HMG gives you both in one injection, which matters because spermatogenesis is a two-signal process — you cannot restore it with LH activity alone.

• LH activity → Leydig cells (LHCGR): Binds the LH/CG receptor, activates Gs/adenylate cyclase → cAMP → PKA → StAR protein upregulation → cholesterol shuttled into mitochondria → intratesticular testosterone (ITT) synthesized via the P450scc/17α-hydroxylase cascade. Same receptor hCG uses, but LH's shorter half-life produces more physiologic pulsatility than hCG's sustained flatline stimulation.
• FSH activity → Sertoli cells (FSHR): Binds the FSH receptor, triggers cAMP/PKA signalling → androgen-binding protein (ABP), inhibin B, and transferrin output → supports spermatogonial proliferation, meiotic progression, and spermatid maturation.

This is why HMG exists in a PED user's toolkit: hCG alone maintains testicular volume and ITT, but does not fully restore sperm output in suppressed users. Sertoli cells need FSH.

"FSH therapy, added to hCG, is required for full restoration of spermatogenesis in most men with hypogonadotropic hypogonadism." — Choi J, Smitz J. Endocrine Reviews, 2018

Intratesticular Testosterone vs Serum Testosterone#

The practical payoff here is a concept most users get wrong: serum T and intratesticular T are not the same thing. Exogenous testosterone saturates serum androgen receptors but leaves ITT collapsed because LH is suppressed. ITT is typically 50–100x higher than serum T in an intact HPTA, and Sertoli cells need that local androgen concentration to support spermatogenesis. HMG's LH component restores Leydig steroidogenesis locally, rebuilding ITT, while its FSH component makes sure Sertoli cells can actually use that ITT to produce sperm. Without both, you get one half of the equation.

Sustained FSH Exposure Through Favorable Kinetics#

FSH has a terminal half-life of roughly 24 hours after SC or IM injection, which is what makes EOD or 3x/week dosing viable. You don't need daily injections to keep Sertoli receptors engaged.

"FSH half-life was approximately 24 hours for the terminal phase after subcutaneous or intramuscular administration, supporting alternate-day dosing." — le Cotonnec JY et al. Fertility and Sterility, 1997

LH activity in HMG clears faster (~10–12 h), but most preparations spike LH bioactivity with hCG to standardize potency, which extends effective LH-receptor drive toward hCG's kinetics. Net result: one SC injection covers both receptor populations for ~24–48 hours.

Downstream Physiological Outcomes#

Tying the receptor-level mechanism back to what the user actually cares about:

This is why protocols are measured in months, not weeks — a complete spermatogenic cycle takes around 74 days, so the earliest meaningful semen analysis is at week 10–12.

Urinary-Derived Protein Considerations#

HMG is purified from urine rather than produced recombinantly, which is why injection-site reactions show up more often than with rFSH products.

"The urinary-derived gonadotrophin preparations, while effective, may contain additional poorly defined urinary proteins that occasionally induce local reactions." — Loutradis D et al. Human Reproduction Update, 2009

Clinically meaningful immunogenicity is rare, but this is the trade-off for HMG being substantially cheaper than recombinant alternatives — and for most users, the cost difference over a 3–6 month fertility protocol is the deciding factor.

Common (most users)#

• Estradiol rise — the most predictable effect. HMG drives intratesticular testosterone, ITT aromatizes, E2 climbs. Mitigation: anastrozole 0.25–0.5 mg 2x/week, titrated to E2 ~25–35 pg/mL. Pull bloods at week 4–6 to catch it before gyno flares.
• Water retention and puffiness — downstream of the E2 climb. Resolves when E2 is controlled; don't chase it with extra AI before you've tested.
• Injection-site reactions (redness, itching, small welts) — more common with urinary-derived preparations than recombinant FSH due to trace non-gonadotropin proteins. Rotate sites, use SC in the abdomen, use a fresh 29–31G insulin pin.

  "The urinary-derived gonadotrophin preparations, while effective, may contain additional poorly defined urinary proteins that occasionally induce local reactions." — Loutradis et al., Human Reproduction Update 2009

• Mild flu-like symptoms, headache, fatigue — first 1–2 weeks as HPG signaling ramps. Transient; no action needed beyond hydration.
• Testicular pressure / mild ache — usually benign Leydig hypertrophy from combined hCG + HMG drive. If it's sharp or localized, pause and rule out epididymal congestion.

Uncommon (dose-dependent or individual)#

• Gynecomastia flare — when E2 control is neglected or anastrozole is under-dosed. Back off HMG frequency, tighten the AI, and if a lump is palpable add a SERM (raloxifene 60 mg/day or tamoxifen 10–20 mg/day) for 4–8 weeks.
• Acne, oily skin, mood volatility — reflect the ITT-driven androgen and E2 swing. Bloodwork: total T, free T, E2 sensitive, SHBG.
• Prolactin elevation — uncommon but seen when 19-nor users run HMG on top of residual nandrolone/trenbolone metabolites. Check prolactin if libido craters or nipples get sensitive.
• Hypertension / hematocrit drift in users simultaneously blasting AAS — not HMG itself, but the compounded androgen load. Standard cycle bloodwork applies (CBC, lipids, BP).
• Sluggish or absent semen response after 8+ weeks — suggests under-dosing or primary testicular pathology. Bump to 150 IU 3x/week and extend to a full 12-week window before calling it a failure; spermatogenesis is a ~74-day cycle.

Rare but serious#

• Anti-FSH antibody formation — reported rarely with urinary preparations; clinically minimal but can blunt response. Switching to recombinant FSH (follitropin alfa/beta) resolves it.
• Thromboembolic events — documented in the female IVF literature at supraphysiologic stimulation; not a clean male-user concern but worth knowing if you're already running hematocrit-elevating compounds. Stop immediately for calf swelling, unexplained shortness of breath, or chest pain.
• Severe local allergic reaction — urticarial rash spreading from the injection site, facial swelling. Stop the compound; switch to recombinant FSH if continuing therapy is necessary.
• Accelerated growth of an occult hormone-sensitive tumor — any LH/FSH-receptor-driving agent is contraindicated in suspected testicular or prostate malignancy. Get a baseline DRE/PSA and testicular exam before starting if you're over 40 or have a family history.

Hard contraindications#

• Active or suspected testicular cancer — do not use.
• Active or suspected prostate cancer — do not use.
• Known pituitary tumor or untreated hyperprolactinemia — treat the cause first; HMG downstream of an unmanaged pituitary lesion is reckless.
• Ongoing suppressive AAS with no exit plan — running HMG while shut down by high-dose AAS is burning money. You'll aromatize the ITT you generate and accomplish little for spermatogenesis. Either cruise on low-dose T only or come off.
• Known hypersensitivity to urinary gonadotropin preparations — switch to recombinant FSH + hCG instead.

Gender and PCT considerations#

HMG is clinically used in both sexes, but the context for this profile is male fertility. In female users (IVF, not a PED context) the dominant risk is ovarian hyperstimulation syndrome (OHSS) — this does not apply to men.

On the PCT question: HMG is not PCT. It replaces what the pituitary should be putting out — it does not restart the pituitary. Running HMG instead of a SERM-based restart in a shut-down user means you're doing hormone replacement, not recovery. The correct framing is:

• Standard PCT after a short cycle in a young user with a functional HPTA: clomiphene/enclomiphene + tamoxifen. HMG is overkill and doesn't train the pituitary back on.

• Fertility preservation during blast-and-cruise: hCG ± periodic HMG blocks. HMG here is a Sertoli-cell maintenance tool, not a restart tool.

• Pre-conception push after long-term AAS: hCG + HMG for 12+ weeks, then layer in a SERM once spermatogenesis is responding. This is where HMG earns its keep.

  "FSH therapy, added to hCG, is required for full restoration of spermatogenesis in most men with hypogonadotropic hypogonadism." — Choi & Smitz, Endocrine Reviews 2018

Used inside its niche — fertility preservation and restoration on or after AAS — HMG is well-tolerated, the side-effect profile is almost entirely downstream of the E2 rise it drives, and an informed user with a functioning AI and routine bloodwork handles it without drama.